Get the latest news, insights, and market updates on ENSC (Ensysce Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
New York, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The research summary below is from a report commissioned by Ensysce Biosciences, Inc. and produced by Diamond Equity Research. The update note includes information on Ensysce Biosciences’ business updates, management commentary, financial results, valuation, and risks. The Nov 17, 2025 - $ENSC
ENSC Bolsters Balance Sheet for Commercialization Push
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that have plagued the American public. The company released its 3Q2025 earnings results that showed a loss of $1.29 per share and Nov 17, 2025 - $ENSC
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~ ~ Further Program Advancement Supported by Preferred Stock Financing ~ SAN DIEGO, CA / ACCESS ... Nov 14, 2025 - $ENSC
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation ... Oct 10, 2025 - $ENSC
ENSC Focused on Bringing Change to Pain Relief Market
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that have plagued the American public. The company released its 2Q2025 earnings results that showed a loss of $0.79 per share and Aug 14, 2025 - $ENSC
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple